跳至主要内容
临床试验/NCT03881683
NCT03881683已完成不适用

Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer

Institut de Cancérologie de Lorraine2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2020年2月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
24
试验地点
2
主要终点
Concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma (SNV, indels)

研究概览

简要总结

BOVARY-Pilot is a monocentric prospective transversal pilot study with a total duration of 6 months. The purpose of this study is to determine the feasibility of detecting somatic tumor mutations in the blood of patients with ovarian cancer in order to determine whether a blood test can replace a tissue biopsy to prescribe a personalized treatment. The method will consist of a single blood sample during the patient's visit and prior to the establishment of any newly diagnosed cancer treatment. The concordance of somatic mutations (SNV) found in tissue and in cell-free DNA (cfDNA) extracted from blood will then be compared

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Patient with stage III to IV non-treated high grade ovarian cancer or recurrent high grade ovarian cancer
  • Adequate haemoglobin rate ≥ 9 g/dL
  • Patient who can benefit from an additional blood sample of 20ml. The total volume of each sample meets with the indications of the Order in force establishing the list of researches mentioned in 2 ° of Article L. 1121-1 of the Public Health Code.
  • Availability of tumor samples from biopsy or surgery
  • Patient affiliated to a social security scheme
  • Ability to provide written informed consent

排除标准

  • Any concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study
  • Contraindication to a blood sample of 20 mL
  • Pregnant or breast-feeding women
  • Ongoing treatment for the newly diagnosed cancer or the recurrence
  • Patient pre-treated with poly-ADP-ribose-polymérase-1 (PARP) Inhibitors
  • Patient under guardianship or curatorship or deprived of liberty.

结局指标

主要结局

Concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma (SNV, indels)

时间窗: 1 day (samples will be analyzed in batch at the end of inclusions)

Number of patients with detected punctual somatic mutations (SNVs and indels of BRCA1/2 and genes involved in HRD) concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma

次要结局

  • Concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma (large rearrangements, LOH, CNV)(1 day (samples will be analyzed in batch at the end of inclusions))

研究者

发起方
Institut de Cancérologie de Lorraine
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Determination of the Feasibility of Tumoural Somatic... | 临床试验